Samsung Bioepis seeks Europe approval for its Humira copy

SEOUL, July 18 (Reuters) - Biosimilars maker Samsung

Bioepis, part of South Korea's top family-run conglomerate

Samsung Group, said on Monday it is seeking regulatory

approval in Europe to sell its copy of AbbVie Inc's

rheumatoid arthritis drug Humira.

Read more